Free Trial

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at HC Wainwright

NewAmsterdam Pharma logo with Medical background

Investment analysts at HC Wainwright started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) in a report released on Monday, Marketbeat Ratings reports. The firm set a "buy" rating and a $48.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 87.50% from the company's current price.

A number of other equities research analysts also recently weighed in on the stock. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a "buy" rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reissued an "overweight" rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $38.17.

Check Out Our Latest Report on NewAmsterdam Pharma

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded down $0.26 during trading on Monday, hitting $25.60. 339,913 shares of the stock were exchanged, compared to its average volume of 377,810. NewAmsterdam Pharma has a 1-year low of $11.18 and a 1-year high of $27.29. The company's fifty day simple moving average is $21.99 and its 200-day simple moving average is $19.17.

Insider Transactions at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the company's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the transaction, the insider now owns 11,150,461 shares in the company, valued at $283,110,204.79. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 428,446 shares of company stock valued at $10,514,105. Corporate insiders own 19.50% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

Hedge funds have recently modified their holdings of the stock. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma during the 2nd quarter worth $38,000. Quarry LP lifted its stake in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC lifted its stake in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares during the period. Bellevue Group AG bought a new position in NewAmsterdam Pharma in the third quarter valued at about $128,000. Finally, XTX Topco Ltd acquired a new stake in NewAmsterdam Pharma in the third quarter worth about $187,000. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

See Also

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Should You Invest $1,000 in NewAmsterdam Pharma Right Now?

Before you consider NewAmsterdam Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.

While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines